The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Safety and Efficacy of Oral Flecainide Therapy in Patients with Atrioventricular Re-entrant Tachycardia

James L. Cockrell, MD; Melvin M. Scheinman, MD; Christina Titus, MS, RN; Ibrahim Helmy, MD; Jonathan J. Langberg, MD; Michael A. Lee, MD; and Jerry C. Griffin, MD
[+] Article, Author, and Disclosure Information

Requests for Reprints: James L. Cockrell, MD, Cardiology Service, Department of Medicine, Letterman Army Medical Center, Presidio of San Francisco, CA 94129-6700.

Current Author Addresses: Dr. Cockrell: Cardiology Service, Letterman Army Medical Center, Presidio of San Francisco, CA 94129-6700.

Dr. Scheinman, Ms. Titus, and Drs. Helmy, Langberg, Lee, and Griffin: Room 312, Moffitt Hospital, Box 0214, University of California, San Francisco, CA 94143.

Ann Intern Med. 1991;114(3):189-194. doi:10.7326/0003-4819-114-3-189
Text Size: A A A

Objective: To assess the short- and long-term safety and efficacy of oral flecainide therapy in patients with symptomatic tachycardia and an extranodal accessory pathway.

Design: Open-label, uncontrolled trial with a mean follow-up of 24 months.

Setting: Referral-based, teaching medical center.

Patients: Sixty-three patients with symptomatic tachycardia and an extranodal accessory pathway.

Interventions: Patients had electrophysiologic testing before and after the initiation of oral flecainide therapy and were followed long-term for the presence of symptoms, new physical limitations, and adverse effects of therapy.

Measurements and Main Results: Flecainide therapy prevented or slowed (324 ± 59 ms to 398 ± 55 ms; P < 0.001) inducible sustained atrioventricular reciprocating tachycardia in 44 of 63 patients (70%). Of the 44 patients discharged from the hospital, 33 (75%) have continued to receive flecainide therapy and have shown no adverse effects (mean follow-up, 24 ± 10 months). Adverse cardiac reactions (proarrhythmia or sinus node suppression) attributable to flecainide occurred in 11 of 63 patients (17%); in 9 (82%) of these 11 patients, events were detected during either in-hospital monitoring or the electrophysiologic study done before discharge. Structural heart disease was detected by two-dimensional echocardiography in 8 of 11 patients who had adverse cardiac events and in 6 of 52 patients who did not have such events (P < 0.001). Isoproterenol reversed the effects of flecainide therapy in 11 of 21 patients; 7 of the 11 patients had spontaneous clinical recurrences of tachycardia or palpitations during the follow-up period, but these symptoms occurred in only 1 of 10 patients who did not show isoproterenol-induced reversal (P = 0.02).

Conclusions: Oral flecainide therapy was effective in 33 of 63 patients who had tachycardia and an extranodal accessory connection. Hospital monitoring during initial therapy is recommended, and flecainide should be used with caution, if at all, in patients with structural heart disease. An isoproterenol challenge appears to be helpful in predicting late recurrence of tachycardia.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Buy Now for $42.00

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Related Articles
Journal Club
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.